Merck, Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) In Combination With KEYTRUDA (pembrolizumab) For Adjuvant Treatment Of Patients With Resected High-Risk (Stage IIB-IV) Melanoma
Portfolio Pulse from Benzinga Newsdesk
Merck and Moderna have initiated a Phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA for adjuvant treatment of patients with resected high-risk melanoma. The first patients are now enrolling in Australia.

July 26, 2023 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck has initiated a Phase 3 study with Moderna, which could potentially lead to a new treatment for melanoma.
The initiation of a Phase 3 study indicates that Merck is progressing in its product pipeline. If successful, this could lead to a new product offering, potentially boosting Merck's revenues and stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Moderna is collaborating with Merck on a Phase 3 study for a potential new melanoma treatment.
Moderna's collaboration with Merck on this Phase 3 study could potentially lead to a new product offering. This could boost Moderna's revenues and stock price if the study is successful.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100